GlycoMimetics (GLYC) Revenue & Revenue Breakdown
GlycoMimetics Revenue Highlights
00
GlycoMimetics Revenue by Period
GlycoMimetics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $74.92K | -93.54% |
| 2021-12-31 | $1.16M | -88.59% |
| 2020-12-31 | $10.16M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2016-12-31 | $18.00K | -99.91% |
| 2015-12-31 | $20.07M | 33.57% |
| 2014-12-31 | $15.03M | 276.37% |
| 2013-12-31 | $3.99M | -73.83% |
| 2012-12-31 | $15.26M | 300.04% |
| 2011-12-31 | $3.81M | - |
GlycoMimetics generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
GlycoMimetics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $10.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $75.00 | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $75.00K | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $18.00K | -79.21% |
| 2021-09-30 | $86.56K | 60857.75% |
| 2021-06-30 | $142.00 | -99.99% |
| 2021-03-31 | $1.06M | 547.51% |
| 2020-12-31 | $163.00K | -83.70% |
| 2020-09-30 | $1.00M | 100.00% |
| 2020-06-30 | - | -100.00% |
| 2020-03-31 | $9.00M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | -100.00% |
| 2016-12-31 | $-500.00 | -102.70% |
| 2016-09-30 | $18.50K | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | -100.00% |
| 2015-12-31 | $35.38K | 100.00% |
| 2015-09-30 | - | -100.00% |
| 2015-06-30 | $20.04M | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | -100.00% |
| 2014-06-30 | $15.03M | 100.00% |
| 2014-03-31 | - | -100.00% |
| 2013-12-31 | $77.41K | 47.25% |
| 2013-09-30 | $52.57K | -4.54% |
| 2013-06-30 | $55.07K | -98.55% |
| 2013-03-31 | $3.81M | -2.08% |
| 2012-12-31 | $3.89M | 1.61% |
| 2012-09-30 | $3.83M | - |
GlycoMimetics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
GlycoMimetics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SPRO | Spero Therapeutics | $96.73M | $13.47M |
| FHTX | Foghorn Therapeutics | $34.16M | $7.81M |
| IVA | Inventiva | $17.50M | $15.58M |
| ASMB | Assembly Biosciences | $7.16M | $6.84M |
| CUE | Cue Biopharma | $5.49M | $3.34M |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| GLYC | GlycoMimetics | - | - |
| ANTX | AN2 Therapeutics | - | - |
| BCAB | BioAtla | - | $11.00M |
| TIL | Instil Bio | - | - |
| DYN | Dyne Therapeutics | - | - |
| TRVI | Trevi Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| ACHL | Achilles Therapeutics | - | - |
| MLYS | Mineralys Therapeutics | - | - |